Rubella Virus Infected Macrophages and Neutrophils Define Patterns of Granulomatous Inflammation in Inborn and Acquired Errors of Immunity.
Aged
Antigens, Viral
/ metabolism
Cohort Studies
Cytokines
/ metabolism
Disease Susceptibility
Female
Genetic Diseases, Inborn
Granuloma
/ immunology
Hematopoietic Stem Cell Transplantation
Humans
Immunohistochemistry
Immunologic Deficiency Syndromes
Inflammation
/ immunology
Macrophages
/ immunology
Male
Middle Aged
Neutrophils
/ immunology
Receptors, Interleukin-1
/ antagonists & inhibitors
Rubella
/ complications
Rubella virus
/ physiology
Th2 Cells
/ immunology
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
granuloma treatments
granulomatous inflammation
inborn errors of immunity
macrophages
neutrophils
primary immunodeficiency
skin lesion
vaccine-derived rubella viruses
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
10
2021
accepted:
30
11
2021
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Rubella virus (RuV) has recently been found in association with granulomatous inflammation of the skin and several internal organs in patients with inborn errors of immunity (IEI). The cellular tropism and molecular mechanisms of RuV persistence and pathogenesis in select immunocompromised hosts are not clear. We provide clinical, immunological, virological, and histological data on a cohort of 28 patients with a broad spectrum of IEI and RuV-associated granulomas in skin and nine extracutaneous tissues to further delineate this relationship. Combined immunodeficiency was the most frequent diagnosis (67.8%) among patients. Patients with previously undocumented conditions, i.e., humoral immunodeficiencies, a secondary immunodeficiency, and a defect of innate immunity were identified as being susceptible to RuV-associated granulomas. Hematopoietic cell transplantation was the most successful treatment in this case series resulting in granuloma resolution; steroids, and TNF-α and IL-1R inhibitors were moderately effective. In addition to M2 macrophages, neutrophils were identified by immunohistochemical analysis as a novel cell type infected with RuV. Four patterns of RuV-associated granulomatous inflammation were classified based on the structural organization of granulomas and identity and location of cell types harboring RuV antigen. Identification of conditions that increase susceptibility to RuV-associated granulomas combined with structural characterization of the granulomas may lead to a better understanding of the pathogenesis of RuV-associated granulomas and discover new targets for therapeutic interventions.
Identifiants
pubmed: 35003119
doi: 10.3389/fimmu.2021.796065
pmc: PMC8728873
doi:
Substances chimiques
Antigens, Viral
0
Cytokines
0
Receptors, Interleukin-1
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
796065Subventions
Organisme : NIAID NIH HHS
ID : R21 AI130967
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI141877
Pays : United States
Informations de copyright
Copyright © 2021 Perelygina, Faisthalab, Abernathy, Chen, Hao, Bercovitch, Bayer, Noroski, Lam, Cicalese, Al-Herz, Nanda, Hajjar, Vanden Driessche, Schroven, Leysen, Rosenbach, Peters, Raedler, Albert, Abraham, Rangarjan, Buchbinder, Kobrynski, Pham-Huy, Dhossche, Cunningham Rundles, Meyer, Theos, Atkinson, Musiek, Adeli, Derichs, Walz, Krüger, von Bernuth, Klein, Icenogle, Hauck and Sullivan.
Déclaration de conflit d'intérêts
MA is employed by Sidra Medicine and Hamad Medical Corporation, Qatar. HB is employed by Labor Berlin GmbH, Germany. JH received grants from Immune Deficiency Foundation, the US immunodeficiency network, Chao-physician Scientist award, the Texas Medical Center Digestive Diseases Center and the Jeffrey Modell Foundation. JH received honorarium, consultation fees from Horizon, Pharming, Baxalta, CSL Behring, the National guard, and Al-Faisal University Hospital. TPA received consultation fees from Horizon, Pharming, CSL Behring. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2020 Aug 06;11:1491
pubmed: 32849507
J Allergy Clin Immunol. 2016 Nov;138(5):1436-1439.e11
pubmed: 27613149
JAMA. 1965 May 24;192:675-81
pubmed: 14280514
J Allergy Clin Immunol. 2022 Jan;149(1):388-399.e4
pubmed: 34033843
J Neurovirol. 2014 Apr;20(2):137-49
pubmed: 24297501
Am J Dermatopathol. 2014 Oct;36(10):832-7
pubmed: 25062261
Annu Rev Immunol. 2012;30:459-89
pubmed: 22224774
JAMA Dermatol. 2019 Jul 1;155(7):859-861
pubmed: 31166586
Prog Med Virol. 1974;18(0):273-88
pubmed: 4608455
Ann Rheum Dis. 1986 Feb;45(2):110-4
pubmed: 3947141
J Pediatr. 1967 Oct;71(4):512-24
pubmed: 6046619
Front Immunol. 2019 Jul 19;10:1272
pubmed: 31379802
Am J Respir Cell Mol Biol. 2011 Aug;45(2):277-86
pubmed: 20971883
Front Immunol. 2021 Jan 20;11:613638
pubmed: 33552077
J Clin Immunol. 2020 Jan;40(1):24-64
pubmed: 31953710
Clin Exp Immunol. 2015 Oct;182(1):45-50
pubmed: 26031847
PLoS Pathog. 2019 Oct 28;15(10):e1008080
pubmed: 31658304
Annu Rev Immunol. 2018 Apr 26;36:639-665
pubmed: 29400999
Clin Microbiol Infect. 2014 Oct;20(10):O656-63
pubmed: 24476349
Clin Immunol. 2010 May;135(2):264-72
pubmed: 20399414
Nat Rev Immunol. 2012 Apr 20;12(5):352-66
pubmed: 22517424
J Clin Immunol. 2019 Jan;39(1):81-89
pubmed: 30607663
JAMA Dermatol. 2021 Jul 1;157(7):842-847
pubmed: 34037685
Blood Rev. 1991 Jun;5(2):71-7
pubmed: 1655129
EBioMedicine. 2014 Oct 30;2(1):59-63
pubmed: 26137534
J Clin Immunol. 2013 May;33(4):716-24
pubmed: 23354909
Teratology. 1998 Jul;58(1):13-23
pubmed: 9699240
J Clin Immunol. 2019 Jan;39(1):112-117
pubmed: 30680653
Front Immunol. 2019 Jul 24;10:1754
pubmed: 31396239
J Clin Immunol. 2018 Aug;38(6):717-726
pubmed: 30043271
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1412-1420
pubmed: 30869812
Expert Rev Clin Immunol. 2018 Dec;14(12):1029-1041
pubmed: 30280610
J Clin Virol. 2015 Aug;69:104-9
pubmed: 26209390
Curr Opin Allergy Clin Immunol. 2020 Dec;20(6):574-581
pubmed: 33044342
Clin Infect Dis. 2017 Jan 1;64(1):83-86
pubmed: 27810866
Clin Rev Allergy Immunol. 2014 Apr;46(2):112-9
pubmed: 23760761
EBioMedicine. 2015 Nov 27;3:86-92
pubmed: 26870820
J Clin Immunol. 2021 Apr;41(3):666-679
pubmed: 33598806
J Cell Death. 2014 May 08;7:15-23
pubmed: 25278783
J Clin Invest. 1984 Dec;74(6):2024-32
pubmed: 6392340
Ocul Immunol Inflamm. 2016 Jun;24(3):348-57
pubmed: 26222767
Front Immunol. 2017 Nov 08;8:1454
pubmed: 29167667
Trends Immunol. 2016 Jun;37(6):386-398
pubmed: 27237815